


RealRate

PHARMACEUTICAL 2020

BOMARIN°

BIOMARIN PHARMACEUTICAL INC Rank 42 of 362





PHARMACEUTICAL 2020



BIOMARIN

BIOMARIN PHARMACEUTICAL INC Rank 42 of 362

The relative strengths and weaknesses of BIOMARIN PHARMACEUTICAL INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BIOMARIN PHARMACEUTICAL INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 259% points. The greatest weakness of BIOMARIN PHARMACEUTICAL INC is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 28% points.

The company's Economic Capital Ratio, given in the ranking table, is 108%, being 411% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	1,942,143
Cost of Goods Sold	359,466
Intangible Assets	653,619
Liabilities, Current	932,503
Liabilities, Non-Current	98,124
Other Assets	1,083,409
Other Compr. Net Income	14,893
Other Expenses	1,605
Other Liabilities	537,031
Other Net Income	29,106
Property and Equipment	1,010,868
Research and Development	715,007
Revenues	1,704,048
Selling, General and Administrative Expense	680,924

Output Variable	Value in 1000 USD
Assets	4,690,039
Liabilities	1,567,658
Expenses	1,757,002
Stockholders Equity	3,122,381
Net Income	-23,848
Comprehensive Net Income	-16,402
Economic Capital Ratio	108%